Phase 2 Clinical Trial of PC(Procarbazine-CCNU) Chemotherapy in Patients With Recurrent or Resistant Glioblastoma With Methylated MGMT
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
6-month progression free survival
March 31, 2014
Yes
Don-Sup Chung, MD
Principal Investigator
Incheon St. Mary Hispital
South Korea: Korea Food and Drug Administration (KFDA)
KNOG-1201
NCT01737346
October 2012
April 2014
Name | Location |
---|